TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16882185

Group type: EXPERIMENTAL
Intervention: 10% ALA-PDT
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 14636346

Group type: EXPERIMENTAL
Intervention: Antiepileptic monotherapy with prednisolone (1 mg/kg/day for 10 days, tapering over 4 days)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Antiepileptic monotherapy alone
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Antiepileptic monotherapy with prednisolone
Number of subjects: 97
Study: 10389804

Group type: EXPERIMENTAL
Intervention: IV dexamethasone 10 mg
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: IV droperidol 1.25 mg
Number of subjects: 120

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 120
Study: 8678277

Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 50

Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 50
Study: 1676594

Group type: EXPERIMENTAL
Intervention: Cimetidine 400 mg
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Atracurium 0.45 mg kg‐1
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Vecuronium 0.08 mg kg‐1
Number of subjects: 72
Study: 6350090

Group type: EXPERIMENTAL
Intervention: Propafenone (900 mg/day)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Lorajmine (600 mg/day)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: After therapy interruption
Number of subjects: 20
Study: 2932514

Group type: EXPERIMENTAL
Intervention: Indomethacin (a cyclooxygenase inhibitor)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Dazoxiben hydrochloride (a thromboxane synthase inhibitor)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: BM13.177 (a thromboxane receptor antagonist)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 29807159

Group type: EXPERIMENTAL
Intervention: NO3‐ supplementation (12 mmol/d)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 27537992

Group type: EXPERIMENTAL
Intervention: CF101 2 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 23918683

Group type: EXPERIMENTAL
Intervention: Hydrocortisone 30 mg divided in 2 doses
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Hydrocortisone 30 mg divided in 4 doses
Number of subjects: 15

Group type: COMPARATOR
Intervention: Patients with AAD
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: CXCL11 levels
Number of subjects: 15
Study: 22128195

Group type: EXPERIMENTAL
Intervention: CMR stress imaging test
Number of subjects: 120

Group type: COMPARATOR
Intervention: Provider-selected stress test (stress echo, CMR, cardiac catheterization, nuclear, coronary CT)
Number of subjects: 120
Study: 20708169

Group type: EXPERIMENTAL
Intervention: Cervical lengths (CLs) ≥25 mm
Number of subjects: 672

Group type: COMPARATOR
Intervention: Cervical lengths (CLs) <25 mm (no cerclage)
Number of subjects: 672
Study: 18726610

Group type: EXPERIMENTAL
Intervention: 0.5% prednisolone acetate eye drops
Number of subjects: 62

Group type: COMPARATOR
Intervention: Vehicle eye drop solution
Number of subjects: 62
Study: 16029343

Group type: EXPERIMENTAL
Intervention: Levamisole 150 mg (or 100 mg for children)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Levamisole
Number of subjects: 60
Study: 14500148

Group type: COMPARATOR
Intervention: General Anesthesia (propofol/nitrous oxide/fentanyl)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Spinal Anesthesia (6 mg bupivacaine and 15 micro g fentanyl)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Psoas Compartment Block (40 mL of 1.5% mepivacaine)
Number of subjects: 60
Study: 10792094

Group type: COMPARATOR
Intervention: High ligation surgery
Number of subjects: 468

Group type: EXPERIMENTAL
Intervention: Microsurgical high inguinal varicocelectomy (MHIV)
Number of subjects: 468
Study: 8704686

Group type: EXPERIMENTAL
Intervention: Interleukin-2 (IL-2) induction course (9 x 10(6) U/m2/day for 5 days) followed by maintenance (0.9 x 10(6) U/m2/day for 10 days)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Interleukin-2 (IL-2) therapy
Number of subjects: 14
Study: 1677910

Group type: EXPERIMENTAL
Intervention: Ficoll fractionated and Mafosfamide purged cells (50 micrograms/ml/1 x 10e7 MN cells)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Untreated buffy-coat marrow derived cells
Number of subjects: 40
Study: 6406454

Group type: EXPERIMENTAL
Intervention: Bupropion (50-450 mg/day to 300-750 mg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Amitriptyline (75-225 mg/day)
Number of subjects: 0
Study: 31677349

Group type: EXPERIMENTAL
Intervention: IPTp‐mefloquine (MQ)
Number of subjects: 914

Group type: COMPARATOR
Intervention: IPTp‐sulphadoxine‐pyrimethamine (SP)
Number of subjects: 914

Group type: COMPARATOR
Intervention: IPTp‐placebo
Number of subjects: 914
Study: 30917561

Group type: EXPERIMENTAL
Intervention: Computerised decision-support tool (DST)
Number of subjects: 65

Group type: COMPARATOR
Intervention: General recommendations (Control Group)
Number of subjects: 65
Study: 28809389

Group type: EXPERIMENTAL
Intervention: Telephone-based support for management of pressure ulcers (12 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 0
Study: 26063787

Group type: EXPERIMENTAL
Intervention: Icodextrin 7.5%
Number of subjects: 60

Group type: COMPARATOR
Intervention: Glucose 2.5%
Number of subjects: 60
Study: 23726175

Group type: EXPERIMENTAL
Intervention: Moxonidine
Number of subjects: 56
Study: 21522088

Group type: EXPERIMENTAL
Intervention: nalbuphine hydrochloride
Number of subjects: 0

Group type: COMPARATOR
Intervention: tramadol hydrochloride
Number of subjects: 0
Study: 20137432

Group type: EXPERIMENTAL
Intervention: Social skills training program (1 hour weekly for 12 weeks)
Number of subjects: 441
Study: 16702893

Group type: EXPERIMENTAL
Intervention: Zolpidem-MR 12.5 mg
Number of subjects: 18

Group type: COMPARATOR
Intervention: Flurazepam 30 mg
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 14769727

Group type: EXPERIMENTAL
Intervention: Emergency department treatment of COPD exacerbation
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Number of urgent clinic or ED visits for COPD exacerbation in the past year
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Self-reported activity limitation during the past 24 h
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Respiratory rate at ED presentation
Number of subjects: 140
Study: 11686543

Group type: EXPERIMENTAL
Intervention: Losartan (25 mg/day)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Enalapril (5 mg/day)
Number of subjects: 16
Study: 9692119

Group type: EXPERIMENTAL
Intervention: Prednisolone 0.5 mg kg-1
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Prednisolone 1.0 mg kg-1
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Prednisolone 2.0 mg kg-1
Number of subjects: 98
Study: 7921938

Group type: EXPERIMENTAL
Intervention: Intravesical epirubicin at a concentration of 1 mg/ml (n = 40)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Intravesical epirubicin at a concentration of 2 mg/ml (n = 41)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Intravesical epirubicin (both concentrations)
Number of subjects: 81
Study: 2908134

Group type: EXPERIMENTAL
Intervention: 6 mg bromazepam
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 12 mg bromazepam
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 31789558

Group type: EXPERIMENTAL
Intervention: SDT-informed weight-loss intervention (SDT-WL)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Standard behavioral weight loss (BWL)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Both conditions (BWL and SDT-WL)
Number of subjects: 64
Study: 31645468

Group type: EXPERIMENTAL
Intervention: Progressive muscle relaxation
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control focused attention
Number of subjects: 64
Study: 27838660

Group type: EXPERIMENTAL
Intervention: 4 mg nicotine inhaler
Number of subjects: 47

Group type: COMPARATOR
Intervention: nicotine administration
Number of subjects: 47
Study: 24831730

Group type: EXPERIMENTAL
Intervention: Community-based skill-building intervention consisting of six to eight 60-minute sessions led by a trained health educator.
Number of subjects: 75

Group type: COMPARATOR
Intervention: Wait-list control group.
Number of subjects: 75
Study: 24347903

Group type: EXPERIMENTAL
Intervention: Hybrid fractionation (6GyX3 fractions on alternate days during the 1st week, followed by 2GyX5 daily fractions in the 2nd week)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Standard fractionation (3GyX5 daily fractions for 2 consecutive weeks)
Number of subjects: 45
Study: 22142767

Group type: EXPERIMENTAL
Intervention: Trans fatty acids in phosphatidylethanolamine (PE)
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Docosahexaenoic acid (DHA) in phosphatidylethanolamine (PE)
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Trans fatty acids and DHA correlation in phosphatidylcholine (PC)
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Trans fatty acids and DHA correlation in phosphatidylethanolamine (PE)
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Trans fatty acids and DHA correlation at 30th week of gestation
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Trans fatty acids and DHA correlation at delivery
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Trans fatty acids and DHA correlation in cord lipids
Number of subjects: 241
Study: 21141000

Group type: EXPERIMENTAL
Intervention: Phacoemulsification
Number of subjects: 182

Group type: COMPARATOR
Intervention: Small Incision Cataract Surgery (SICS)
Number of subjects: 182

Group type: COMPARATOR
Intervention: SICS
Number of subjects: 182
Study: 16473752

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment (10 sessions over 2 weeks)
Number of subjects: 6
Study: 12738015

Group type: EXPERIMENTAL
Intervention: Mannitol 20%
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: NaCl 7.5%
Number of subjects: 30

Group type: COMPARATOR
Intervention: NaCl 0.9% (Control)
Number of subjects: 30
Study: 10695943

Group type: EXPERIMENTAL
Intervention: Intraoral fluoride releasing device (IFRD) consisting of sodium fluoride encased in an acrylic polymer, releasing fluoride at approximately 0.04 mg/day
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo device
Number of subjects: 49
Study: 9085402

Group type: EXPERIMENTAL
Intervention: Buprenorphine (4, 8, 16 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Hydromorphone (9 and 18 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Maintenance buprenorphine plus challenge buprenorphine
Number of subjects: 8
Study: 8335191

Group type: EXPERIMENTAL
Intervention: Azathioprine (2.5 mg/kg body weight) combined with prednisolone (60 mg daily tapering to 10 mg)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Prednisolone (60 mg daily tapering to 10 mg) monotherapy
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Azathioprine (2.5 mg/kg body weight) combined with prednisolone
Number of subjects: 42

Group type: COMPARATOR
Intervention: Prednisolone monotherapy
Number of subjects: 42
Study: 2883488

Group type: EXPERIMENTAL
Intervention: Doxycycline (100 mg daily)
Number of subjects: 188

Group type: COMPARATOR
Intervention: Chloroquine (300 mg base weekly)
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Doxycycline
Number of subjects: 188
Study: 29215954

Group type: EXPERIMENTAL
Intervention: 0.2% ropivacaine (intraperitoneal group)
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: 0.2% ropivacaine (intraincisional group)
Number of subjects: 244

Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 244
Study: 27608926

Group type: EXPERIMENTAL
Intervention: THPP+ intervention (bimonthly group‐based sessions for 36 months)
Number of subjects: 560

Group type: COMPARATOR
Intervention: Control group (perinatally nondepressed women)
Number of subjects: 560
Study: 24525661

Group type: EXPERIMENTAL
Intervention: Org 25935 (4 to 8 mg twice daily)
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: Org 25935 (12 to 16 mg twice daily)
Number of subjects: 215

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 215
Study: 23212499

Group type: EXPERIMENTAL
Intervention: Clinically integrated e-learning EBM course
Number of subjects: 204

Group type: COMPARATOR
Intervention: Self-directed EBM course
Number of subjects: 204
Study: 20162706

Group type: EXPERIMENTAL
Intervention: Intravesical gemcitabine (2000 mg/50 mL) twice weekly for 6 weeks, then weekly for 3 weeks at 3, 6, and 12 months
Number of subjects: 80

Group type: COMPARATOR
Intervention: Intravesical BCG (Connaught strain, 81 mg/50 mL) over a 6-week induction course and weekly for 3 weeks at 3, 6, and 12 months
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Intravesical gemcitabine
Number of subjects: 80

Group type: COMPARATOR
Intervention: Intravesical BCG
Number of subjects: 80
Study: 18417130

Group type: EXPERIMENTAL
Intervention: Low-intensity pulsed ultrasound
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 0
Study: 15917336

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PTF) 1200 mg daily
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control group (no PTF)
Number of subjects: 61
Study: 14699228

Group type: EXPERIMENTAL
Intervention: Pyridostigmine omitted on the night before surgery (Group 1)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Pyridostigmine continued with morning dose on the day of surgery (Group 2)
Number of subjects: 14
Study: 10805066

Group type: EXPERIMENTAL
Intervention: Gavestinel 800 mg loading dose followed by 100-, 200-, or 400-mg maintenance doses every 12 hours for five doses
Number of subjects: 0
Study: 8857482

Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 7963447

Group type: EXPERIMENTAL
Intervention: Sertraline 50-100 mg/day
Number of subjects: 3396

Group type: COMPARATOR
Intervention: Dothiepin 75-150 mg/day
Number of subjects: 3396

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3396

Group type: EXPERIMENTAL
Intervention: Sertraline 50 mg/day
Number of subjects: 3396
Study: 3308579

Group type: EXPERIMENTAL
Intervention: Buffy coat transfusions (approximately 0.6 X 10(9) T-lymphocytes) weekly for 5 weeks
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (no buffy coat transfusions)
Number of subjects: 22
Study: 29417834

Group type: EXPERIMENTAL
Intervention: teen Mental Health First Aid (tMHFA)
Number of subjects: 1942

Group type: COMPARATOR
Intervention: Physical First Aid (PFA)
Number of subjects: 1942
Study: 27327608

Group type: EXPERIMENTAL
Intervention: ABM training towards affective pain words (S+A+)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: ABM training towards sensory pain words (S+A-)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: ABM training away from affective pain words (S-A+)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: ABM training away from sensory pain words (S-A-)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 106
Study: 24763133

Group type: EXPERIMENTAL
Intervention: Vedolizumab 750 mg
Number of subjects: 127

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 127
Study: 23865726

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate/formoterol (flutiform) 250/10 µg b.i.d.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate/formoterol (flutiform)
Number of subjects: 0

Group type: COMPARATOR
Intervention: SKP FP
Number of subjects: 0

Group type: COMPARATOR
Intervention: GSK FP
Number of subjects: 0
Study: 22352202

Group type: EXPERIMENTAL
Intervention: Lamotrigine (LTG) therapy added to NIAAA protocol for 2004
Number of subjects: 240

Group type: COMPARATOR
Intervention: NIAAA protocol for 2004 (Control group)
Number of subjects: 240
Study: 19043252

Group type: EXPERIMENTAL
Intervention: Candesartan (ARB)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Calcium channel blocker (CCB; amlodipine or nifedipine)
Number of subjects: 0
Study: 17190587

Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy
Number of subjects: 1719

Group type: EXPERIMENTAL
Intervention: Mini-laparotomy cholecystectomy
Number of subjects: 1719

Group type: COMPARATOR
Intervention: Open cholecystectomy
Number of subjects: 1719

Group type: EXPERIMENTAL
Intervention: Non-randomised patients
Number of subjects: 1719

Group type: COMPARATOR
Intervention: Trial patients
Number of subjects: 1719
Study: 12747340

Group type: EXPERIMENTAL
Intervention: Low flow anesthesia
Number of subjects: 40

Group type: COMPARATOR
Intervention: High flow anesthesia
Number of subjects: 40
Study: 10959505

Group type: EXPERIMENTAL
Intervention: Conventional overnight co-incubation of sperm and oocytes
Number of subjects: 0

Group type: COMPARATOR
Intervention: Short (2-h) co-incubation of sperm and oocytes
Number of subjects: 0
Study: 8580386

Group type: EXPERIMENTAL
Intervention: IL-8 levels
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: IL-6 levels
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Elastase-alpha 1-AT levels
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: IL-8 and IL-6 interrelation
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: IL-8 and elastase complexes
Number of subjects: 13
Study: 2550642

Group type: EXPERIMENTAL
Intervention: Lisinopril 20 mg once daily
Number of subjects: 304

Group type: COMPARATOR
Intervention: Captopril 50 mg once daily
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Lisinopril 20 mg once daily with hydrochlorothiazide 25 mg
Number of subjects: 304

Group type: COMPARATOR
Intervention: Captopril 50 mg once daily with hydrochlorothiazide 25 mg
Number of subjects: 304
Study: 363215

Group type: EXPERIMENTAL
Intervention: Highly selective vagotomy (HSV)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Truncal vagotomy and pyloroplasty (TVP)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Highly selective vagotomy (HSV) and Truncal vagotomy and pyloroplasty (TVP)
Number of subjects: 126
Study: 31082267

Group type: EXPERIMENTAL
Intervention: Information film + written information booklet
Number of subjects: 229
Study: 28785746

Group type: EXPERIMENTAL
Intervention: Refurbishment (A: n = 21)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Replacement (B: n = 21)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Untreated (C: n = 21)
Number of subjects: 23
Study: 26181802

Group type: EXPERIMENTAL
Intervention: Playing a videogame with a sexualized female character for 15 minutes
Number of subjects: 57

Group type: COMPARATOR
Intervention: Control condition (playing a videogame with a nonsexualized female character)
Number of subjects: 57
Study: 23123272

Group type: EXPERIMENTAL
Intervention: Carbohydrate-electrolyte solution (CES)
Number of subjects: 10
Study: 21964278

Group type: EXPERIMENTAL
Intervention: Symptom-based classification methods
Number of subjects: 115
Study: 18624823

Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Laparoscopic colectomy
Number of subjects: 241
Study: 16672214

Group type: EXPERIMENTAL
Intervention: Coleus amboinicus Lour (CA) supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Molocco+B12 tablets
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fenugreek seeds
Number of subjects: 0
Study: 15610110

Group type: EXPERIMENTAL
Intervention: Vardenafil 10 mg (with option to titrate to 5, 10, or 20 mg)
Number of subjects: 463

Group type: EXPERIMENTAL
Intervention: Vardenafil
Number of subjects: 463

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 463
Study: 11377409

Group type: EXPERIMENTAL
Intervention: Naltrexone (started at 25 mg/day, titrated up to 250 mg/day)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 83
Study: 8113283

Group type: EXPERIMENTAL
Intervention: Patients with radiographic signs of prosthetic loosening
Number of subjects: 49

Group type: COMPARATOR
Intervention: Patients without radiographic signs of prosthetic loosening
Number of subjects: 49
Study: 3336109

Group type: EXPERIMENTAL
Intervention: Silver oxide coating of the indwelling urethral catheter and catheter adapter, and instillation of trichloroisocyanuric acid into the urinary drainage bag
Number of subjects: 74

Group type: COMPARATOR
Intervention: Control group (standard catheter care)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Trichloroisocyanuric acid
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Systemic antimicrobial agents
Number of subjects: 74
Study: 31880494

Group type: EXPERIMENTAL
Intervention: HIV/HBV/HCV co-infection
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: HIV/HBV co-infection
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: HIV/HCV co-infection
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: Triple infection
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: HIV/HCV infection rate
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: HBV co-infection
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: Co-infection rates among widowed patients
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: High-risk behavior
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: Other risk factors
Number of subjects: 311
Study: 30406565

Group type: COMPARATOR
Intervention: Anti-citrullinated α-enolase peptide 1 antibodies (a-CEP-1)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Anti-mutated citrullinated vimentin antibodies (a-Sa)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Anti-caramylated protein antibodies (a-CarP)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Anti-hnRNP/RA33 antibodies (a-hnRNP/RA33)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Anti-filaggrin antibodies (AFAs)
Number of subjects: 74
Study: 28950361

Group type: EXPERIMENTAL
Intervention: GAVS II risk model applied to the validation group
Number of subjects: 18054
Study: 26632177

Group type: EXPERIMENTAL
Intervention: 0.5% Rice Bran Supercritical CO2 Extract (RB-SCE) applied dermally (8 mL/d) for 16 weeks
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo applied dermally for 16 weeks
Number of subjects: 50